You are here

Screen for Inhibitors of Mycobacterial RNA Polymerase

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 AI38688-01,
Agency Tracking Number: 29143
Amount: $82,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
200 Boston Avenue, Suite 3000
Medford, MA 02155
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 James Lillie
 () -
Business Contact
Phone: () -
Research Institution

Tuberculosis (TB) is the leading cause of death from any single infectious agent for much of the wois estimated that one third of the world's population carries a latent TB infection. Most alarming adrug-resistant TB. Rifampicin is currently a treatment of choice, but there is a growing resistancerifampicin and its analogs and therefore an important need for new therapies. The goal of this reseadiscover novel classes of antibiotics for the treatment of drug-resistant mycobacteria. A high throuestablished for the discovery of new inhibitors of rifampicin-resistant RNA polymerase of M. tubercuUsing purified M. smegmatis as a model system, RNA polymerase resistant to rifampicin and rifabutinpurified and used to develop a robust, reliable assay for screening a library of synthetic organic cproducts for compounds which inhibit RNA polymerase. Once active compounds have been identified, thefor potency, specificity and toxicity, and promising compounds will ultimately be developed into antthrough medicinal chemistry.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government